Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.

<h4>Objective</h4>The capacity of the non-nucleoside reverse transcriptase inhibitor efavirenz to induce either liver CYP3A4 or intestinal CYP3A4, or both, as well as intestinal P-glycoprotein, was evaluated in healthy volunteers during and after a 10-day treatment course with two different daily do... View More